MedTrace Logo

Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion

NCT02018445 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-02-18

Study results available
· View outcomes & findings →

Summary

The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented posterolateral spine fusion, as compared to local autograft.

Conditions

  • Degenerative Changes
  • Stenosis
  • Spondylosis

Interventions

PROCEDURE

Posterolateral Fusion

Sponsors & Collaborators

  • SeaSpine, Inc.

    lead INDUSTRY

Principal Investigators

  • Philip Yuan, M.D · Memorial Orthopaedic Surgical Group

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-07-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02018445 on ClinicalTrials.gov